Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 78

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 8
Chunk 78
---
 unaudited financial statements do not include any adjustments that might result from the outcome
of this uncertainty.

Registration
Rights

The
holders of the Founder Shares, Private Placement Units (and underlying securities) and any Private Placement Units (and underlying
securities) that may be issued on conversion of working capital loans are entitled to registration rights pursuant to a registration
rights agreement requiring the Company to register such securities for resale. The holders of these securities are entitled to make up
to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have
certain piggy-back registration rights with respect to registration statements filed subsequent to the completion of the initial Business
Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act.
However, the registration rights agreement will provide that the Company will not be required to effect or permit any registration or
cause any registration statement to become effective until termination of the applicable lock-up period. The Company will bear the expenses
incurred in connection with the filing of any such registration statements.

14

DRUGS
MADE IN AMERICA ACQUISITION CORP.

NOTES
TO FINANCIAL STATEMENTS

SEPTEMBER
30, 2025

(Unaudited)

Underwriting
Agreement

The
Company granted the underwriters a 45-day option from the date of the final prospectus dated January 27, 2025, to purchase up to 3,000,000
additional Units to cover over-allotments, if any, at the Initial Public Offering price less the underwriting discounts and commissions.
On February 18, 2025, the underwriters exercised their option in full to purchase an additional 3,000,000 Units at a purchase price of
$10.00 per Unit, generating additional gross proceeds of $30,000,000.

The
underwriters were entitled to a cash underwriting discount of $0.05 per Unit, or 0.5% of the gross proceeds of the Initial Public Offering,
or $1,000,000 in the aggregate (or up to $1,150,000 if the over-allotment option is exercised in full), paid at the closing of the Initial
Public Offering and the $150,000 was paid on the closing of the over-allotment option. In addition, the underwriters are entitled to
a deferred fee of $0.30 per Unit,